# Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

> **NCT01034917** · PHASE3 · COMPLETED · sponsor: **Germans Trias i Pujol Hospital** · enrollment: 43 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Etravirine 400 mg dissolved in water every 24 hours
- **DRUG:** Continue with the same antiretroviral regimen

## Key facts

- **NCT ID:** NCT01034917
- **Lead sponsor:** Germans Trias i Pujol Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034917, "Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01034917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*